Flerie AB approved a transaction to transfer its Limited Partnership segment investments to T&M Participation AB, enhancing liquidity and reducing outstanding commitments by approximately SEK 150 million.

Information on the Target

The Extraordinary General Meeting of Flerie AB (publ), registered under the number 559067-6820, convened on December 29, 2025, at 11:00 CET. During this meeting, significant resolutions were made regarding a related-party transaction.

The proposal approved by the Board of Directors involves transferring Flerie’s investments in the Limited Partnership segment to T&M Participation AB, owned by the Company's Chairman, Thomas Eldered. This transaction adheres to the rules governing related-party transactions set forth in Chapter 16a of the Swedish Companies Act (SFS 2005:551), ensuring compliance and transparency.

Industry Overview in Sweden

Sweden is renowned for its robust life sciences sector, characterized by a high level of innovation and research activity. The country hosts numerous biotechnology and pharmaceutical companies, which contri

View Source

Similar Deals

Industrifonden Zymego

2026

Other VC Healthcare Facilities & Services (NEC) Sweden
Flerie Invest AB Nanologica AB (publ)

2025

Public-to-Private (P2P) Biotechnology & Medical Research (NEC) Sweden
Flerie AB (publ) Toleranzia AB (publ)

2025

Buyout Biopharmaceuticals Sweden
Sciety Hälsa Hemma

2025

Other VC Hospitals, Clinics & Primary Care Services Sweden
ANTCO. Investment Group AB (publ) Deversify AB

2025

Other Healthcare Facilities & Services (NEC) Sweden
ANTCO. Investment Group AB (publ) Dynamic Code AB (publ)

2025

Other Healthcare Facilities & Services (NEC) Sweden

T&M Participation AB

invested in

Flerie AB

in 2025

in a Other Corporate deal

Disclosed details

Transaction Size: $11M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert